The Technical Analyst
Cogint Inc. [COGT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cogint Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-4.55% $7.56
America/New_York / 10 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 722.84 mill |
| EPS: | -2.49 |
| P/E: | -3.04 |
| Earnings Date: | Aug 05, 2024 |
| SharesOutstanding: | 95.61 mill |
| Avg Daily Volume: | 2.08 mill |
| RATING 2024-05-10 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.04 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.52x |
| Company: PE -3.04 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.432 (-94.29%) $-7.13 |
| Date: 2024-05-10 |
| Expected Trading Range (DAY) |
|---|
|
$ 7.10 - 8.02 ( +/- 6.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Ferrante Karen Jean | Buy | 3 213 | Stock Option (Right to Buy) |
| 2024-03-28 | Fairmount Funds Management Llc | Buy | 286 851 | Common Stock |
| 2024-03-28 | Fairmount Funds Management Llc | Buy | 11 914 | Series A Convertible Preferred Stock |
| 2024-03-28 | Fairmount Funds Management Llc | Sell | 11 914 | Series A Convertible Preferred Stock |
| 2024-03-28 | Fairmount Funds Management Llc | Sell | 286 851 | Common Stock |
| INSIDER POWER |
|---|
| 87.94 |
| Last 97 transactions |
| Buy: 19 542 341 | Sell: 1 316 263 |
Forecast:
16:00 - $7.56
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $7.56
Forecast 2: 16:00 - $7.56
Forecast 3: 16:00 - $7.56
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.56 (-4.55% ) |
| Volume | 0.799 mill |
| Avg. Vol. | 2.08 mill |
| % of Avg. Vol | 38.36 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For COGT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $6.32 | N/A | Active |
|---|
COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-05-07 08:00:00 - Press Release
Cogent Biosciences Reports First Quarter 2024 Financial Results
Summit, peak and apex registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025
2024-04-18 09:00:00 - Press Release
Shareholder Alert: Purcell & Lefkowitz Llp Announces Shareholder Investigation Of Cogent Biosciences, Inc. (nasdaq: Cogt)
New york , april 18, 2024 /prnewswire/ -- purcell & lefkowitz llp announces that it is investigating cogent biosciences, inc. (nasdaq: cogt) on behalf of the company's shareholders. the investigation seeks to determine whether cogent biosciences, inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
2024-04-09 09:00:00 - Press Release
Cogent Biosciences Presents Data Highlighting Potential Best-in-class Potency And Selectivity Of Novel, Egfr Sparing, Cns-penetrant Erbb2 Inhibitor
Waltham, mass. and boulder, colo.
2024-02-26 08:00:00 - Press Release
Cogent Biosciences Reports Recent Business Highlights And Fourth Quarter And Full Year 2023 Financial Results
• ummit part 2 registration-directed study of bezuclastinib in nonadvsm patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as rp2d; topline results expected by ye 2025
2024-02-22 14:30:00 - Press Release
Cogent Biosciences Announces Positive Part 1b Data From Summit Trial Evaluating Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis
Registration-enabling summit part 2 initiated and actively enrolling at 40 sites globally; rp2d selected at 100 mg once-daily optimized formulation based on:
Latest News
2024-02-05 09:00:00 - GlobeNewsWire
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET
2023-12-11 08:23:00 - Market Watch
Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment
Cogent Biosciences Inc. shares COGT, -1.48% fell more than 30% premarket on Monday after the company over the weekend released clinical trial data on its lead drug candidate that failed to outshine potential competitors, in analysts' view. In a trial of bezuclastinib in patients with nonadvanced systemic mastocytosis, a rare blood disorder in which too many mast cells build up in the body, everyone treated with the therapy achieved at least 50% improvement in all relevant biomarker measures, Cogent said Friday at the American Society of Hematology annual meeting in San Diego.
2023-07-07 11:23:48 - GuruFocus
3 Lost Formula Stocks to Consider for the 2nd Half of 2023
Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.
2023-05-23 08:00:00 - GlobeNewsWire
Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
2023-04-12 08:00:00 - GlobeNewsWire
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual investor conferences:
2023-03-06 22:55:40 - 24/7 Wall Street
These Are the Top 10 Holdings of David Kim
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).
2023-02-28 02:17:45 - Seeking Alpha
Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal Tumors
Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointestinal Stromal Tumors. Bezuclastinib is a promising tyrosine kinase inhibitor that targets KIT exon 17/18 mutations, commonly found in patients with advanced and/or treatment-resistant GIST.
2022-12-27 19:02:21 - Seeking Alpha
Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now
Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline.
2022-12-05 08:00:00 - GlobeNewsWire
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 64th American Society of Hematology (ASH) Annual Meeting.
2022-09-13 13:16:07 - Seeking Alpha
Cogent Biosciences: What's Ahead
Today, we put Cogent Biosciences, Inc. in the spotlight for the first time in nearly two years. Cogent stock has roughly tripled since positive trial data came out in June, and the company has addressed its current funding needs.